top of page


FDA approves Biocon's Pebrilzo pertuzumab biosimilar for HER2-positive breast cancer
Biocon has secured US FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, expanding its oncology biosimilar portfolio while commercial entry remains subject to a patent settlement allowing launch from the third quarter of 2028.

nuaxia
1 day ago2 min read


Biocon and Genentech reach global Pebrilzo biosimilar patent settlement establishing launch dates
Biocon and Genentech have reached a global patent settlement and licence agreement establishing planned launch windows for Pebrilzo, Biocon's pertuzumab biosimilar to Perjeta.

nuaxia
Oct 152 min read


Ascendis and BioMarin agree global Yuviwel patent settlement and licence
The binding term sheet resolves litigation between Ascendis Pharma and BioMarin while granting Ascendis a worldwide licence covering YUVIWEL and other navepegritide-related products.

nuaxia
Sep 12 min read
bottom of page